WallStSmart
LAB

Standard Biotools Inc

NASDAQ: LAB · HEALTHCARE · MEDICAL DEVICES

$0.93
+4.69% today

Updated 2026-04-30

Market cap
$350.48M
P/E ratio
P/S ratio
4.11x
EPS (TTM)
$-0.15
Dividend yield
52W range
$1 – $2
Volume
2.7M

Standard Biotools Inc (LAB) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
+60.0%
Last 4 quarters
Revenue YoY growth
-93.1%
Most recent quarter
EPS YoY growth
+236.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-2.7%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-8.1%
2025-11-04
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-18$0.07+226.1%$1.12$1.15+2.7%
2025-11-04$-0.09-80.0%$1.24$1.14-8.1%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.05$0.07+226.1%$3.22M-93.1%
2025-09-30$-0.05$-0.09-80.0%$19.55M-56.5%
2025-06-30$-0.07$-0.03+60.1%$21.76M-3.2%
2025-03-31$-0.04$-0.05-19.5%$40.80M-10.4%
2024-12-31$-0.03$-0.05-64.7%$46.72M+65.7%
2024-09-30$-0.09$-0.07+22.2%$44.97M+77.3%
2024-06-30$-0.08$-0.12-50.0%$22.49M-18.7%
2024-03-31$-0.12$-0.27-125.0%$45.54M+81.3%
2023-12-31$-0.13$-0.25-92.3%$28.19M
2023-09-30$-0.12$-0.27-125.0%$25.37M
2023-06-30$-0.21$-0.22-4.8%$27.67M
2023-03-31$-0.06$-0.11-98.9%$25.12M

Frequently asked questions

Has Standard Biotools Inc beaten earnings estimates?
Standard Biotools Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of +60.0% over the last 3 quarters.
How does LAB stock react to earnings?
LAB stock has moved an average of -2.7% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Standard Biotools Inc's revenue growth rate?
Standard Biotools Inc reported year-over-year revenue growth of -93.1% in its most recent quarter, with EPS growing +236.0% year-over-year.